International BBBD Consortium
The International Blood-Brain Barrier Disruption (BBBD) Consortium
is directed from OHSU, and combines basic science, research and comprehensive
patient
care to treat patients with brain tumors.
OHSU has developed protocols and guidelines for opening the blood-brain
barrier with input from the universities participating
in the International BBBD Consortium.
The International BBBD Consortium is coordinated from OHSU by
Nancy Doolittle, Ph.D., R.N.
The
International BBBD Consortium includes the following universities and
foundations:
Ohio
State University Medical Center
|
Columbus,
Ohio
Program Director: John McGregor, M.D.
(614) 293-5440
Clinical
Study Coordinator: Susan Bell, R.N., M.S.
(614) 293-3143
|
| Cleveland
Clinic Foundation |
Cleveland,
Ohio
Program
Director: Gene H. Barnett,
M.D.
(216)
444-5381
Clinical
Study Coordinators:
Sandra Ference, M.S.N., R.N., C.N.P.
(216) 444-5381
Lisa Sorenson, M.S.N., R.N., A.C.N.P.
(216) 444-5381 |
|
|
Oklahoma
City, Oklahoma
Program Director: Mary Kay Gumerlock,
M.D.
(405) 271-4912
Clinical
Study Coordinator: Carol Young, R.N.
(405) 271-4912 |
| University
of Minnesota |
Minneapolis,
Minnesota
Program Director: Stephen Haines, M.D.
(612) 626-5767
Clinical
Study Coordinator: Katie Halbert, R.N.
(612) 273-4713 |
| Hadassah-Hebrew
University Medical Center |
Jerusalem,
Israel
Program Director: Tali Siegal, M.D.
972 2 677-6951 |
| University
of Kentucky Hospital |
Lexington,
Kentucky
Program
Director: Byron Young, M.D.
(859) 323-5864
|
| Centre
Hospital Universitaire De Sherbrooke |
Quebec,
Canada
Program
Director: David Fortin, M.D.
(819) 346-1110 |
Protocols currently open at BBBD Consortium centers:
Primary Central Nervous
System Lymphoma |
| A Phase I/II Study of Patients with Newly Diagnosed
Primary Central Nervous System Lymphoma Treated with Methotrexate/BBBD,
and Adding Rituximab (an anti CD-20 Antibody) and Carboplatin
to the Treatment Regimen |
- Oregon Health & Science
University, IRB #1012
|
- Cleveland
Clinic Foundation, IRB #BBBC1306-CC038
|
| A Phase II Trial Involving Patients
with Recurrent PCNSL Treated with Carboplatin/BBBD, by Adding
Rituxan
(Rituximab),
an anti CD-20 Antibody, to the Treatment Regimen |
- Oregon Health & Science
University, IRB #641
|
- University of Oklahoma, IRB
#10195
|
- Ohio State University Medical Center,
IRB #2003C0068
|
- Hadassah-Hebrew University Medical Center, IRB #20030737
|
| Phase II Clinical Trial of Patients
with High-Grade Glioma Treated with Intra-arterial Carboplatin-based
Chemotherapy,
Randomized to Treatment with or without Delayed Intravenous
Sodium Thiosulfate as a Potential Chemoprotectant against Severe
Thrombocytopenia |
- Oregon Health & Science
University, IRB #922
|
- Cleveland
Clinic Foundation, IRB #6385
|
Anaplastic Oligodendroglioma |
| Phase I/II Study of Carboplatin, Melphalan and Etoposide
Phosphate in Conjunction with Osmotic Opening of the Blood-Brain
Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection,
in Subjects with Anaplastic Oligodendroglioma or Oligoastrocytoma |
- Oregon Health & Science
University, IRB #8507
|
|